Lam Research has staged one of its sharpest weekly recoveries in recent memory, with the price reversal from last week's note making the prior article's cautionary tone look very dated very fast.
The move is the story. LRCX closed at $322.68 on Tuesday, up 18% on the week and more than 20% over the past month — a dramatic reversal from the $273 level flagged in last week's note, where the Morgan Stanley upgrade had visibly failed to hold. The stock has now blown through the Street's mean target of $312, which means analyst targets that looked ambitious a week ago are already behind the tape. The closest peer in performance terms is KLAC, which gained 14.5% on the week, while AMAT added 10% and ASML lagged at just under 10% — LRCX clearly led the group rather than moved with it.
The most decisive analyst action came this morning, when Mizuho's Vijay Rakesh raised his target from $330 to $380, keeping his Outperform rating intact. That is the highest target in the recent changes data and the only one to come in above the current price, which frames the current tape well: the stock has effectively caught up with the prior wave of post-earnings upgrades from late April, when JP Morgan, RBC, TD Cowen, Citi, and Stifel all nudged targets into the $310–$340 range after a solid quarterly print. Morgan Stanley's upgrade to Overweight on May 18 with a $331 target — the catalyst that failed to hold last week — now looks correct in direction, just early in timing. The consensus has tilted firmly bullish, with the analyst recommendation differential ranking in the 96th percentile versus the broader universe.
Bulls point to Lam's dominant market share in etch and deposition, strong NAND and foundry exposure, and a Piotroski F-score of 9 with an Altman Z-score of 12.3 that signals robust financial health. Bears flag the same NAND exposure as a double-edged sword — demand cycles in memory can inflect quickly — and cite ongoing China regulatory risk as a structural overhang. The PE ratio has expanded to roughly 49x and EV/EBITDA to 40x, both up meaningfully over 30 days as the stock re-rated. Those are not cheap multiples for a cyclical equipment maker, and Barclays, the lone Equal-Weight holdout in the recent-changes data with a $275 target, remains well below the pack — a reminder that not everyone on the Street is chasing the print higher.
Short positioning offers no drama to match the price action. Short interest edged down slightly on the week to 2.38% of the free float — roughly 29.9 million shares — and has barely moved in either direction despite the stock's 18% gain. The ORTEX short score sits at 33.1, essentially unchanged from where it has traded for weeks. Borrow availability is exceptionally loose, at over 9,000% relative to short interest, meaning there is essentially no squeeze dynamic in play. Cost to borrow has ticked up about 58% on the week to 0.55%, which sounds dramatic in percentage terms but remains trivial in absolute cost — well below any level that constrains short sellers. The lending market is simply not a factor in either direction here.
Options traders are mildly more cautious than average, with the put/call ratio at 1.07 — slightly above its 20-day mean of 1.05 but only 0.7 standard deviations elevated, well short of any extreme reading. The 52-week range for PCR runs from 0.94 to 1.37, and the current reading sits near the lower end. That implies options positioning has not shifted to reflect panic hedging; investors appear comfortable with the risk into the next earnings date on July 30.
Insider activity leans one way: the last 90 days show net selling. CFO Doug Bettinger sold across three tranches in late February and early March at prices between $224 and $234. With the stock now at $322, those sales look poorly timed in hindsight — the CFO sold at a roughly 28% discount to where the stock printed this week. Whether that colours how the market reads future insider activity is worth monitoring as July earnings approach.
The next test is the July 30 print. After two prior quarters where the one-day reaction was modest (essentially flat in April 2026) and the five-day reaction was more negative (down 3.7% and 12% respectively), the question is whether the re-rating to above $320 has pulled forward expectations far enough to raise the bar for the next result.
See the live data behind this article on ORTEX.
Open LRCX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
